Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
Metabolic health studies: Researching peptides that support healthier body composition
PrRP in the AP ( C ) with vehicle, ( D ) with liraglutide, ( E ) with semaglutide, ( F ) with GLP-1R costaining, ( G ) with TH costaining, and ( H ) PrRP and TH in NTS
Retatrutide (LY3437943) is Eli Lillys experimental triple-agonist drug that activates: GLP-1 (Glucagon-like peptide-1) reduces appetite and slows digestion GIP (Glucose-dependent insulinotropic peptide) enhances insulin sensitivity Glucagon receptor increases fat metabolism and energy expenditure In phase-2 trials, Retatrutide achieved up to 24% body-weight reduction rivaling or even surpassing bariatric surgery outcomes
Caution and awareness of adverse events associated with biologics are advised, as well as a good understanding of vaccination, pregnancy, and surgery with biologic treatment for these patients
Important For research purposes only
US$ 22.61
US$ 21.80
US$ 21.29
US$ 22.37
